Introduction: What they say:
A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33), by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Anti-infective Therapy: A pharmaceutical mixture encompassing Rilpivirine and aspirin inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15
What is known?
Prof. Stephen Elledge research team has showed that interferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.
From research findings to therapeutic opportunity:
This study suggests, for the first time, that a pharmaceutical mixture encompassing Rilpivirine and aspirin , by increasing the expression of its target genes, it may increase the expression of interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides. Thereby, it may: (1) inhibit the replication of Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses; (2) confer resistance against infection caused by Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytical, Sindbis, and SFV viruses; and (3) promote innate immunity (Figure 1). Thus, pharmacological formulations encompassing “Rilpivirine and aspirin or their analogues, either alone or in combination with other drugs” may be used to prevent/treat infections caused by Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses (Figure 2).
Details of the research findings:
Idea formulated by Dr L Boominathan PhD
Undisclosed information: How a pharmaceutical mixture encompassing Rilpivirine and aspirin increases the expression of Antiviral Protein IFITM3, , Interferon-stimulated gene 15, & Mx2
Amount: $ 500#
# Research cooperation
For more details on payment, you may reach us at admin@genomediscovery.org
References:
Citation: Boominathan L, Anti-infective Therapy: A pharmaceutical mixture encompassing Rilpivirine and aspirin inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 23/January/2018, 5.26 am
Courtesy: When you cite drop us a line at info@genomediscovery.org, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
